A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
about
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in CancerThe multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cellsGalectins and their ligands: negative regulators of anti-tumor immunityA major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion.Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanomaDifferences in TCR-Vβ repertoire and effector phenotype between tumor infiltrating lymphocytes and peripheral blood lymphocytes increase with age.The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells.Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attackHuman breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cellsGalectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.The determinants of tumour immunogenicity.Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and GalactomannansEngineering galectin-glycan interactions for immunotherapy and immunomodulationImmune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesThe inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship.Glycobiology of immune responsesCollagen Extracted from Persian Gulf Squid Exhibits Anti-Cytotoxic Properties on Apple Pectic Treated Cells: Assessment in an In Vitro Bioassay Model.Sticking to sugars at the metastatic site: sialyltransferase ST6GalNAc2 acts as a breast cancer metastasis suppressor.Galectin-1 and immunotherapy for brain cancer.Metabolism, LXR/LXR ligands, and tumor immune escape.The sweet and bitter sides of galectins in melanoma progression.Why is melanoma so metastatic?Galectin-3 inhibitors: a patent review (2008-present).Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.Comparative studies on the anti-tumor activities of high temperature- and pH-modified citrus pectins.Strategies to reverse melanoma-induced T-cell dysfunctionPharmacological inhibition of galectin-3 protects against hypertensive nephropathy.Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.Sugars boost exhausted tumor-infiltrating lymphocytes by counteracting immunosuppressive activities of galectinsAssociation between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancerLoss of effector function of human cytolytic T lymphocytes is accompanied by major alterations in N- and O-glycosylation.Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer.Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity.
P2860
Q26744538-6A21858C-57F5-475F-816B-62A74400E454Q26858844-D7214ABA-F8DB-4E18-B780-0B68753F3DB6Q27024580-01BB23AC-761B-4888-9BF8-105450032841Q27335048-45176184-E56C-4291-A94D-E6DA0D17DC5EQ29994573-E6B93A41-B716-436E-963F-5C3B6DF7309BQ30578330-04E8D73D-2C1C-4791-8D1A-E8F97BE960D0Q33849567-562198FB-3E7D-4695-92E6-AF1D15717BEEQ33895977-E87EA847-D004-4C71-9F75-03933FBA6622Q34146327-16C5890E-656E-4D5F-AF25-188CFD0CD2C9Q34580297-A9D0F364-866F-4048-92C4-F04BFB83E06DQ35208414-3B63D078-3A3F-42D3-A132-DC8B582C2C41Q35329234-8714B663-E886-44E1-BCC2-19D4C40F54A9Q36294909-3E85C901-09A8-4AF0-BF65-3B1AE4CA3309Q36440083-E93296DD-CFE5-425E-BF34-D224F0669A6FQ36555524-295DC756-E8A1-43B1-9CC9-333448514425Q37065931-A90D3466-CB1D-49BA-9AFE-670F28322953Q37107168-5808348D-8118-4719-9E52-EDB25A7D529AQ37137360-1761B347-2BE5-4A67-B22F-2B41E78C52D2Q37333778-2C526DC6-08E8-4937-AE63-7DFD1975DD5AQ37448685-11D98B6A-9D26-4CBE-A20E-FFDDB38F3643Q37478076-B78221DC-B6A6-4B2D-8EA8-78F196F1FA15Q37661404-C958A249-2D7F-4B8D-B097-20C3F1C45274Q37862237-C350B35F-59D4-479E-8912-CA276EC8683FQ37902800-7C6B425E-81B5-40B9-A831-6AB7E19DAAFAQ38016538-F4A950E5-261A-4A93-9C09-EA54EF83C1ADQ38150869-05B8C37F-7ADF-497F-97AE-30967DDA2126Q38238525-4B9A0466-5F7D-41EE-861E-93A9B2CCBCD7Q38844576-E5107F23-E506-41A1-B250-87F61BC4CEA1Q39152161-76BEA590-09FA-4AA8-98BF-DDA2BF9E96E3Q40785322-4A9276F8-B67A-492E-8F7C-5B70322E9EA9Q41695164-AFA0B489-259A-42C2-87B3-4854E3C96BC7Q41911091-2D354B01-9B27-48B7-9E28-33F6B27CA6F3Q41936870-48AC0222-AD20-45D0-94FC-2A5799422E26Q42177420-9F80205E-FB84-46C9-9A93-E8F92F7BA576Q42551955-61382F62-386C-4DB7-AD58-0DC89D55DBA5Q44533312-645EAE4F-1ED2-4E3D-AB01-BC435E77A9B9Q47209071-EEF1C741-1317-4450-A0F9-F204147A106EQ47653100-A7A6D4A1-09A8-4232-9D82-215C0E036BD1Q48270428-25089984-FEBD-4DBC-A40E-56F53DC8371EQ49361458-2C3149E3-41A6-4751-89C5-7A437F69C2E1
P2860
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A galectin-3 ligand corrects t ...... avors tumor rejection in mice.
@en
A galectin-3 ligand corrects t ...... avors tumor rejection in mice.
@nl
type
label
A galectin-3 ligand corrects t ...... avors tumor rejection in mice.
@en
A galectin-3 ligand corrects t ...... avors tumor rejection in mice.
@nl
prefLabel
A galectin-3 ligand corrects t ...... avors tumor rejection in mice.
@en
A galectin-3 ligand corrects t ...... avors tumor rejection in mice.
@nl
P2093
P1433
P1476
A galectin-3 ligand corrects t ...... avors tumor rejection in mice.
@en
P2093
Birgit Weynand
Christophe Lurquin
Christopher Schmidt
Grégoire Wieërs
Javier Carrasco
Kris Thielemans
Muriel Moser
Nathalie Demotte
Pierre J Courtoy
Pierre van der Bruggen
P304
P356
10.1158/0008-5472.CAN-10-0761
P407
P577
2010-08-18T00:00:00Z